Aclaris Therapeutics (NASDAQ:ACRS) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a research report issued to clients and investors on Tuesday. The brokerage set an “overweight” rating on the biotechnology company’s stock.

Other equities analysts have also issued research reports about the stock. Scotiabank began coverage on shares of Aclaris Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price objective on the stock. Leerink Partnrs upgraded shares of Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 19th. HC Wainwright upgraded shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 price objective on the stock in a report on Monday, December 23rd. Piper Sandler upgraded shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $3.00 to $13.00 in a report on Monday, November 18th. Finally, StockNews.com lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 8th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Aclaris Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $11.67.

Aclaris Therapeutics Trading Up 1.3 %

Shares of NASDAQ ACRS opened at $1.58 on Tuesday. The firm’s 50-day moving average price is $2.23 and its 200-day moving average price is $2.21. Aclaris Therapeutics has a 1-year low of $0.95 and a 1-year high of $5.17. The firm has a market capitalization of $170.51 million, a P/E ratio of -3.04 and a beta of 0.48.

Institutional Investors Weigh In On Aclaris Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ACRS. Assenagon Asset Management S.A. grew its position in shares of Aclaris Therapeutics by 113.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 397,362 shares of the biotechnology company’s stock valued at $985,000 after acquiring an additional 211,585 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Aclaris Therapeutics by 187.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company’s stock valued at $382,000 after acquiring an additional 216,826 shares during the period. Geode Capital Management LLC grew its position in shares of Aclaris Therapeutics by 9.3% during the 3rd quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company’s stock valued at $974,000 after acquiring an additional 72,309 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in shares of Aclaris Therapeutics during the 3rd quarter valued at approximately $1,053,000. Finally, Peapod Lane Capital LLC bought a new position in shares of Aclaris Therapeutics during the 4th quarter valued at approximately $1,003,000. 98.34% of the stock is owned by institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.